These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23668915)

  • 1. It may be possible to delay the onset of neurodegenerative diseases with an immunosuppressive drug (rapamycin).
    Aso E; Ferrer I
    Expert Opin Biol Ther; 2013 Sep; 13(9):1215-9. PubMed ID: 23668915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases.
    Mendelsohn AR; Larrick JW
    Rejuvenation Res; 2011 Aug; 14(4):437-41. PubMed ID: 21851176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fighting neurodegeneration with rapamycin: mechanistic insights.
    Bové J; Martínez-Vicente M; Vila M
    Nat Rev Neurosci; 2011 Jul; 12(8):437-52. PubMed ID: 21772323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 fatty acids in neurodegenerative diseases: focus on mitochondria.
    Eckert GP; Lipka U; Muller WE
    Prostaglandins Leukot Essent Fatty Acids; 2013 Jan; 88(1):105-14. PubMed ID: 22727983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms mediating brain and cognitive reserve: experience-dependent neuroprotection and functional compensation in animal models of neurodegenerative diseases.
    Nithianantharajah J; Hannan AJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):331-9. PubMed ID: 21112312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive and therapeutic effects of rapamycin, a mammalian target of rapamycin inhibitor, on food allergy in mice.
    Yamaki K; Yoshino S
    Allergy; 2012 Oct; 67(10):1259-70. PubMed ID: 22913509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease?
    Cai Z; Zhao B; Li K; Zhang L; Li C; Quazi SH; Tan Y
    J Neurosci Res; 2012 Jun; 90(6):1105-18. PubMed ID: 22344941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw.
    Spires TL; Hannan AJ
    FEBS J; 2005 May; 272(10):2347-61. PubMed ID: 15885086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nortriptyline delays disease onset in models of chronic neurodegeneration.
    Wang H; Guan Y; Wang X; Smith K; Cormier K; Zhu S; Stavrovskaya IG; Huo C; Ferrante RJ; Kristal BS; Friedlander RM
    Eur J Neurosci; 2007 Aug; 26(3):633-41. PubMed ID: 17686041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olfactory dysfunction in Parkinson's disease.
    Wszolek ZK; Markopoulou K
    Clin Neurosci; 1998; 5(2):94-101. PubMed ID: 10785834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective properties of resveratrol in different neurodegenerative disorders.
    Albani D; Polito L; Signorini A; Forloni G
    Biofactors; 2010; 36(5):370-6. PubMed ID: 20848560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of creatine.
    Beal MF
    Amino Acids; 2011 May; 40(5):1305-13. PubMed ID: 21448659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling.
    Wei C; Amos CI; Zhang N; Wang X; Rashid A; Walker CL; Behringer RR; Frazier ML
    Clin Cancer Res; 2008 Feb; 14(4):1167-71. PubMed ID: 18281551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling neurodegenerative diseases in Caenorhabditis elegans.
    Li J; Le W
    Exp Neurol; 2013 Dec; 250():94-103. PubMed ID: 24095843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration?
    Shirooie S; Nabavi SF; Dehpour AR; Belwal T; Habtemariam S; Argüelles S; Sureda A; Daglia M; Tomczyk M; Sobarzo-Sanchez E; Xu S; Nabavi SM
    Pharmacol Res; 2018 Sep; 135():37-48. PubMed ID: 29990625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin: an anti-cancer immunosuppressant?
    Law BK
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E; Crews L; Masliah E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.